Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
February 01 2023 - 5:00PM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage
biopharmaceutical company focused on the development of orally
administered treatments for type 1 diabetes (T1D), today announced
the appointment of Elizabeth (Betzy) Keiley as Executive Vice
President and General Counsel, effective immediately.
“We welcome Betzy to vTv. Her years of legal expertise and deep
experience in life sciences will be valuable to the vTv team,” said
Paul Sekhri, President and Chief Executive Officer of vTv
Therapeutics. “Her decades of experience in both private practice
and corporate settings make her an ideal fit for this position. I
am confident that we will benefit from her contributions and look
forward to working closely with her as we move ahead toward our
long-term capital funding goals and launching our phase 3 clinical
trials.”
Ms. Keiley is an accomplished life science industry attorney who
has served in multiple senior-level legal positions at publicly
traded biotechnology, diagnostic and medical device companies. She
joins vTv from Entasis Therapeutics Holdings Inc., where she served
as General Counsel. Prior to Entasis, she was Senior Vice
President, General Counsel at Oxford Immunotec, where she
simultaneously served for seven years as Chief Compliance Officer,
and was Assistant General Counsel, Americas, of Zimmer, Inc., a
subsidiary of Zimmer Holdings, Inc. Before beginning her corporate
career in 2008, Ms. Keiley was a partner at Wildman, Harrold, Allen
& Dixon LLP in Chicago, Illinois, where she focused on a wide
range of corporate and commercial matters for clients in a variety
of industries, including medical devices. Ms. Keiley earned her
bachelor’s degree in Psychology and Philosophy from Boston College
and a J.D. from Loyola University School of Law.
“With the upcoming initiation of our pivotal studies of TTP399,
the company is approaching a key inflection point with the
potential to become a commercial organization in the coming years,”
added Ms. Keiley. “I am eager to put my skills and expertise to
work as we continue to advance the development of TTP399 toward our
ultimate goal of changing the treatment paradigm for patients with
T1D.”
About vTv TherapeuticsvTv Therapeutics
Inc. is a clinical stage biopharmaceutical company focused on
developing oral, small molecule drug candidates. vTv has a pipeline
of clinical drug candidates led by programs for the treatment of
type 1 diabetes and cystic fibrosis related diabetes. vTv’s
development partners are pursuing additional indications in type 2
diabetes, chronic obstructive pulmonary disease, renal disease,
primary mitochondrial myopathy, and pancreatic cancer. For more
information, please visit www.vtvtherapeutics.com.
Forward-Looking Statements
The statements made in this release may include forward-looking
statements regarding (i) diabetes market and other markets, (ii)
the development and clinical trial process, regulatory approval
process and attributes of investigational and marketed products to
treat these diseases and other conditions, and (iii) the future
operations, fund-raising activities, expenditures, opportunities
and financial performance of vTv Therapeutics Inc.
These forward-looking statements are only estimates based upon
the information available to vTv Therapeutics Inc. (or the party
preparing such forward-looking statements) as of the date of this
release. The forward-looking statements included herein involve
known and unknown risks and uncertainties and other important
factors such that actual future operations, opportunities, product
development processes and outcomes, clinical trial processes and
outcomes, regulatory approval processes and outcomes, economic
performance of products, fund-raising activities and financial
performance may differ materially from those set forth in or
implied in these forward-looking statements. These risks,
uncertainties, and other factors, which may not be within our
control, are discussed in more detail in our quarterly and annual
reports filed with the Securities and Exchange Commission,
including, without limitation, under the captions, “Risk Factors,”
“Cautionary Note Regarding Forward-Looking Statements” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations.” Therefore, you should read this release in
conjunction with such meaningful cautionary statements.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date hereof. Except as
required by law, we expressly disclaim any responsibility to
publicly update or revise our forward-looking statements, whether
as a result of new information, future events or otherwise. All
forward-looking statements contained herein are qualified in their
entirety by the foregoing cautionary statements.
This release is being provided to you for information purposes
only. This release does not constitute an offer or sale of (or the
solicitation of an offer to buy) any securities of vTv Therapeutics
Inc. or any of its subsidiaries.
This release should not be relied upon for making any investment
decision with respect to any securities of vTv Therapeutics Inc. or
any of its subsidiaries. Any investment decision made with respect
to any such securities should be based solely on an offering
document relating to such securities (if any), including the
information incorporated by reference therein.
Contacts:
Investors:
Lee Roth
Burns McClellan
lroth@burnsmc.com
Media:
Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusain@burnsmc.com / rflamm@burnsmc.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jul 2024 to Aug 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2023 to Aug 2024